key: cord-0880526-xl7ofz69
authors: Nardo, Alexander D.; Schneeweiss‐Gleixner, Mathias; Bakail, May; Dixon, Emmanuel D.; Lax, Sigurd F.; Trauner, Michael
title: Pathophysiological mechanisms of liver injury in COVID‐19
date: 2020-11-29
journal: Liver Int
DOI: 10.1111/liv.14730
sha: d2f180f35975797b100a545637ae24ff4c43e727
doc_id: 880526
cord_uid: xl7ofz69

The recent outbreak of coronavirus disease 2019 (COVID‐19), caused by the Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) has resulted in a world‐wide pandemic. Disseminated lung injury with the development of acute respiratory distress syndrome (ARDS) is the main cause of mortality in COVID‐19. Although liver failure does not seem to occur in the absence of pre‐existing liver disease, hepatic involvement in COVID‐19 may correlate with overall disease severity and serve as a prognostic factor for the development of ARDS. The spectrum of liver injury in COVID‐19 may range from direct infection by SARS‐CoV‐2, indirect involvement by systemic inflammation, hypoxic changes, iatrogenic causes such as drugs and ventilation to exacerbation of underlying liver disease. This concise review discusses the potential pathophysiological mechanisms for SARS‐CoV‐2 hepatic tropism as well as acute and possibly long‐term liver injury in COVID‐19.

Coronaviridae family members, including SARS-CoV-2, SARS-CoV and MERS-CoV, are enveloped viruses, characterized by a positive single-stranded RNA genome of about 30Kb. [8] [9] [10] The angiotensin-converting enzyme 2 (ACE2) has been established as the main viral receptor for SARS-CoV and SARS-CoV-2 11, 12 ( Figure 1 ). Following attachment to the host cell and viral S protein priming by the host transmembrane serine protease 2 (TMPRSS2), 13 SARS-CoV is internalized by endocytosis and the viral genome is released from the endosome. 14, 15 In the cytosol, the viral RNA is translated into two polyproteins, pp1a and pp1ab, that are further processed to produce 16 non-structural proteins (nsp1 to nsp16), 16 the building blocks of the viral replicase-transcriptase complex (RTC). 17, 18 The full viral genome is then replicated in RTC-containing vesicles. 19, 20 In parallel, a set of specific sub-genomic mRNA is generated 14 for the production of SARS-CoV structural and accessory proteins, which assemble to form the nucleocapsid and viral envelope at the ER-Golgi intermediate compartment, allowing the subsequent release of mature virions 21 (Figure 1 ).

Although COVID-19 primarily affects the respiratory system, emerging evidence highlights the impact of this viral infection on other organ systems. [3] [4] [5] 22, 23 The ubiquitous distribution of the main viral entry receptor ACE2 may explain how SARS-CoV-2 is able to cause a widespread disease characterized by systemic organ involvement including the intestines, 24 heart, kidneys, pancreas, liver, muscular and nervous system. 11, [25] [26] [27] [28] In contrast to SARS-CoV-2-induced lung and myocardial injury, the clinical significance of liver involvement has been controversially debated from the very beginning of the COVID-19 pandemic. 22, [28] [29] [30] [31] [32] [33] However, the scientific progress over the last months has shed more light on several key questions concerning COVID-19-associated liver injury. In this review, we will highlight molecular evidence pointing towards a putative hepatic tropism of SARS-CoV-2, and further review pathophysiological mechanisms that could explain the hepatic phenotypes associated with COVID-19.

F I G U R E 1 SARS-CoV-2 life cycle in host cells. SARS-CoV-2 attachment to host cells in liver (eg hepatocytes) may be mediated by the interaction of Spike (S) protein with ACE2. S protein is cleaved by the transmembrane serine protease 2 (TMPRSS2), allowing the cellular entry of the virus. Once uncoated, the viral genome ((+) vgRNA) is released and translated by the ribosome into pp1a and pp1ab (not shown), that are further cleaved into 16 non-structural proteins (nsps). Following the viral replication/transcription complex (vRTC) assembly, nsp6 (in red) induces autophagosome formation, where viral replication might take place (purple dashed lines). Viral replication might also occur in double-membrane vesicles (DMV) (black dashed lines). nsp6-mediated inhibition of autophagosome/lysosome expansion might prevent viral degradation (purple dashed inhibitory line). Newly synthesized viral structural and accessory proteins assemble to form the nucleocapsid and viral envelope at the ER-Golgi intermediate compartment (lower right). Mature virions are then released through the exploitation of the host vesicular system (upper right). DMV and autophagosomes might also be used by the virus for exocytosis and release of mature virions (black dashed lines)

COVID-19 associated liver injury is defined as any liver damage occurring during disease course and treatment of COVID-19 patients, with or without pre-existing liver disease. 4, [34] [35] [36] [37] [38] [39] This includes a broad spectrum of potential pathomechanisms including direct cytotoxicity from active viral replication of SARS-CoV-2 in the liver, 40, 41 immunemediated liver damage due to the severe inflammatory response/ systemic inflammatory response syndrome (SIRS) in COVID- 19, 42 hypoxic changes induced by respiratory failure, vascular changes due to coagulopathy, endothelitis or cardiac congestion from right heart failure, drug-induced liver injury and exacerbation of underlying liver disease ( Figure 2 ). The incidence of elevated liver transaminases (ALT and AST) in COVID-19 patients ranges from 2.5% to 76.3%. 35, 38, 43, 44 In a recent meta-analysis, the pooled rate for AST and ALT outside the reference range was 20%-22.5% and 14.6%-20.1% respectively. 35, 45 These abnormalities can be accompanied by slightly increased total bilirubin levels in up to 35% of cases. 35, 38, 43, 44 While elevations of cholestatic liver enzymes [alkaline phosphatase (ALP) and gamma glutamyl transferase (γGT)] were initially considered rather rare, 4, 22, 23, 46 recent systemic reviews highlight elevations of ALP and γGT in 6.1% and 21.1% of COVID-19 patients respectively. 35, 45 Moreover, a biphasic pattern with initial transaminase elevations followed by cholestatic liver enzymes has been reported, which could reflect SIRS-induced cholestasis at the hepatocellular/canalicular level or more severe bile duct injury in the later stage of the disease. 47 Although COVID-19-associated liver injury has been reported to be mild, it may affect a significant proportion of patients, especially those with a more severe disease course. In F I G U R E 2 Proposed pathophysiology for liver injury upon SARS-CoV-2 infection. COVID-19-associated hepatocellular damage is mainly characterized by moderate steatosis, lobular and portal inflammation, apoptotic/necrotic foci and elevation of plasma ALT and AST (upper left panel). Preliminary observations suggest that the injury might be caused by hepatocellular infection with direct cytopathic effects of SARS-CoV-2, which could induce mitochondrial dysfunction and ER stress contributing to steatosis. Furthermore, SARS-CoV-2 infection might also activate mTOR, which eventually inhibits autophagy (as a mechanism of viral degradation) and facilitates viral escape from the immune system. In addition, cytokine storm, hypoxic conditions due to ARDS and drug-induced liver injury (DILI) may contribute. COVID-19-associated cholangiocellular injury has also been observed and is mainly characterized by bile duct proliferation, occasionally bile plug formation and elevation of plasma γGT and ALP (lower left panel). From a hepatological perspective, COVID-19-positive patients may be divided into three categories: patients without pre-existing chronic liver disease, patients with early stage chronic liver disease and patients with advanced chronic liver disease/cirrhosis. COVID-19-associated liver injury may have a more severe outcome in patients with preexisting liver disease, such as non-alcoholic fatty liver disease (NAFLD) and associated metabolic comorbidity. Moreover, COVID-19 may induce hepatic decompensation with increased mortality in cirrhotic patients (right panel) the light of the central role of the liver for the production of albumin, acute phase reactants and coagulation factors, hepatic dysfunction may impact on the multisystem manifestations of COVID-19 such as ARDS, coagulopathy and multiorgan failure. [2] [3] [4] [5] [6] [7] 48 Moreover, the liver is the primary metabolic and detoxifying organ in the human organism, and even a moderate loss of hepatic function could alter the safety profile and therapeutic efficacy of antiviral drugs metabolized in the liver. Hence, it is crucial to understand the causes of COVID-19-associated liver injury in more detail.

So far, systematic information on underlying histopathological alterations is scarce. Hepatic steatosis (in part microvesicular) and

Kupffer cell activation appear to be commonly encountered in livers of SARS-CoV-2-infected deceased, together with vascular alterations including derangement of intrahepatic portal vein branches, usually mild lobular and portal inflammation, ductular proliferation and liver cell necrosis. 40, 46, [49] [50] [51] Of note, examination of liver biopsies from a cohort of 48 deceased COVID-19 patients revealed extensive luminal thrombosis at the portal and sinusoidal level, together with portal fibrosis accompanied by significant pericyte activation. 51

The presence of SARS-CoV-2 viral RNA has recently been demon- Given recent, although still limited, discoveries, 40,51,52 hepatic tropism for SARS-CoV-2 and direct cytopathic effects should be considered as potential mechanism of COVID-19 associated liver injury, although a classic hepatitic picture has not been reported. 40, 46, [49] [50] [51] The availability of viral receptors at the host cell surface is a major determinant of viral tropism for a specific tissue. 53 As such, SARS-CoV-2 cell entry is mediated by the S protein of the virus, which specifically interacts with host ACE2 and TMPRSS2 ( Figure 1 ). In order to understand whether SARS-CoV-2 might be able to infect liver cells, we explored the expression pattern of the human ACE2 and TMPRSS2 proteins using the Human Protein Atlas (data available at https://www.prote inatl as.org/ENSG0 00001 30234 -ACE2/tissue and https://www.prote inatl as.org/ENSG0 00001 84012 -TMPRS S2/ tissue). Interestingly, the expression levels of the two proteins is highest in intestine and gall bladder, but it appears to be virtually absent in the liver. These data might be incomplete or lack sensitivity, since in the Human Protein Atlas ACE2 expression also seems to be absent in the lungs, where infection is definitely known to occur.

In a recent study, Chai and colleagues applied single-cell RNAseq to healthy human liver samples and found that ACE2 expression levels in bile duct epithelium (cholangiocytes) is comparable to that of alveolar cells in the lungs, whereas hepatocellular ACE2 expression is low but still detectable. 54 Further confirmation of significant ACE2 and TMPRSS2 expression in liver parenchymal cells comes from bio-informatics analyses from the single-cell transcriptome database Single Cell Portal. 55 Interestingly, sinusoidal endothelial cells appear to be ACE2-negative, in line with previous observations. 56 This finding may be important considering recent reports on endothelitis of large intrahepatic vessels caused by SARS-CoV-2 48,57 and high ACE2 expression in other endothelia, including central and portal veins, which also can become infected by the virus. 51 Of note, studies in both mice and humans revealed increased hepatic ACE2 expression in hepatocytes upon liver fibrotic/cirrhotic conditions 58,59 (and our own unpublished observations). This finding may be of great relevance since pre-existing liver injury could thereby exacerbate SARS-CoV-2 hepatic tropism. Moreover, hypoxia, which is a typical feature in severe COVID-19 cases, has been shown to be a main regulator of hepatocellular ACE2 expression. 58 This might explain why extra-pulmonary SARS-CoV-2 dissemination is mainly observed in patients manifesting ARDS and other hypoxic conditions. Importantly, inflammatory conditions/diseases in the liver, as shown for other organs, 60,61 could also upregulate ACE2 expression. Since drug-induced liver injury (DILI) may contribute to liver injury in COVID-19 patients, 62 it might be of interest to explore whether DILI or certain drugs induce hepatic ACE2 over-expression.

In vitro experiments also showed that the S protein of lineage B beta-coronaviruses significantly increases the affinity for its receptor when it is pre-incubated with trypsin, that is when it is proteolytically activated. 63 Since liver epithelial cells express trypsin 64 and a plethora of other serine-proteases which constantly remodel the extracellular matrix, 65 ACE2 expression required for SARS-CoV-2 target and recognition in the liver might be lower than in other tissues with reduced extracellular proteolytic activity. 66 In line with these findings, it has been recently discovered that the S protein of SARS-CoV-2 bears a furin-like proteolytic site never observed before in other coronaviruses of the same lineage. 67 Interestingly, furin is predominantly expressed in organs that have been proposed as permissive for SARS-CoV-2 infection, such as salivary glands, kidney, pancreas (data for The Human Protein Atlas, available at https:// www.prote inatl as.org/ENSG0 00001 40564 -FURIN/ tissue) and the liver. 55 Finally, other factors, as for example ganglioside (GM1), 68 might influence S protein-ACE2 interaction. Therefore, research should also explore more deeply the S protein-ACE2 interactome to achieve new molecular and therapeutic insights.

In a recent report, Ou and colleagues tested pseudovirions containing the SARS-CoV-2 S protein for their ability to infect different cell lines. Interestingly, HuH7 cells, a hepatocyte cell line, as well as Calu3 cells, a human lung carcinoma cell line, were more efficiently transfected by viral vectors carrying the SARS-CoV-2 S protein than control pseudovirions. 69 Moreover, these studies revealed that viral entry might depend on the PIKfyve-TCP2 endocytotic pathway. A crosscheck in the Human Protein Atlas revealed that both PIKfyve and TPC2 are expressed in liver and gall bladder at comparable levels as in the lung (data available at https://www.prote inatl as.org/ ENSG0 00001 15020 -PIKFY VE/tissue and https://www.prote inatl as.org/ENSG0 00001 62341 -TPCN2/ tissue), highlighting the potential relevance of this pathway for hepatic tropism, which therefore expands from simple targeting and recognition to support of intracellular viral replication.

In an effort to establish a new and effective functional viromics A reliable source of information comes from recent work by Yang and colleagues, who demonstrated SARS-CoV-2 tropism for hepatocytes using organoids obtained from human pluripotent stem cell (hPSC)-derived hepatocyte and primary adult human hepatocytes. 73 In these systems, pseudovirions expressing SARS-Cov-2 S protein were able to infect human hepatocytes, while SARS-CoV-2 infection resulted in robust viral replication. 73 Gene expression analyses also showed that SARS-CoV-2-infected primary hepatocytes over-express pro-inflammatory cytokines, while downregulating key metabolic processes, as reflected by the inhibition of CYP7A1, CYP2A6, CYP1A2 and CYP2D6 expression. 73 Finally, Wang and colleagues applied electron microscopy imaging to liver samples of two deceased COVID-19 patients, and identified viral structures in hepatocytes which distinctively resemble SARS-CoV-2 virions. 40 This raises the possibility that the histopathological alterations seen in these patients may be caused by direct cytopathic effects of SARS-CoV-2 40 although a typical hepatitis pattern appears to be lacking. 40, 46, [49] [50] [51] However, further studies with larger biopsy/autopsy cohorts and the combined imaging (including immune electron microscopy) may be necessary to confirm these preliminary observations of hepatocellular SARS-CoV-2 presence.

production and flow as well in immune response. 74 Single-cell sequencing of human long-term liver ductal organoid cultures showed preservation of ACE2 and TMPRSS2 expression. 75 whereas bile from two other small sample series tested negative. 24, 49 These discrepancies might rely on the fact that the positive-tested bile sample has been obtained during surgical resolution of bile duct obstruction, 76 whereas the negatively tested bile was obtained from 48h post-mortem autopsies. 24, 49 Tight junctions allow cholangiocytes to act as a protective barrier for parenchymal liver cells from toxic bile components. Viral infec- 78 and is induced by pro-inflammatory and pro-fibrotic cues, such as Angiotensin II, generated by the catalytic action of ACE as part of the pro-fibrotic branch of the renin-angiotensin system. 79 Of note, ACE2 counteracts ACE function by producing the anti-inflammatory and anti-fibrotic Angiotensin-(1-7) and thereby decreasing the Angiotensin II/Angiotensin-(1-7) ratio. 79 However, ACE2 expression has neither been detected in quiescent, nor in fibrogenic/ activated hepatic stellate cells. 58, [80] [81] [82] [83] These findings suggest that these cells may be a rather non-permissive host for SARS-CoV-2.

Nevertheless, the pro-inflammatory milieu generated by direct or 

Microvesicular and macrovesicular steatosis have been observed in liver autopsies of COVID-19 patients who presented with SARS-CoV-2 infection as the only risk factor for liver injury, and in some cases, SARS-CoV-2 hepatocellular infection has been proven. 40, 49 Importantly, hepatic lipid accumulation as a result of SARS-CoV-2 infection must be differentiated from pre-existing NAFLD, which has been shown to increase the risk for poor outcome in COVID-19 patients. 50 Deregulated in host lipid metabolism and mitochondrial activity as a result of potential direct SARS-CoV-2 cytopathic effects and/or immunopathology induced by cytokine storm, as well as drug side effects (eg corticosteroids) may be important contributors to the development of hepatic steatosis in COVID-19 ( Figure 2 ). Microvesicular steatosis is typically caused by genetic or acquired mitochondrial β-oxidation defects. 94 Preliminary observations suggest that SARSR-CoV-2 affects mitochondrial activity. 95 Furthermore, Wang et al also identified mitochondrial crista abnormalities in liver specimen of COVID-19 patients. 40 Interestingly, impaired mitochondrial activity has also been implicated in the pathogenesis of NAFLD/NASH. 96 Thus, SARS-CoV-2 infection might even worsen the metabolic state and aggravate pre-existing NAFLD by these mechanisms.

Endoplasmic reticulum (ER) stress is known to induce de novo lipogenesis in hepatocytes. 97 Several studies have implicated SARS-CoV infection in the induction of ER stress. For instance, significant up-regulation of ER stress markers glucose-regulated protein 78 (GRP78) and GRP94 has been observed upon SARS-CoV infection in several cell lines. [98] [99] [100] The coronavirus S protein seems to be a major burden for the host ER and might play a key role in ER stress induction. 98, 99 Rearrangement of intracellular membranes by extensive depletion of lipid components from the ER during SARS-CoV-2 infection may also contribute to ER stress. 20 Moreover, the ER stress-related PERK-eIF2-α pathway is over-activated upon SARS-CoV infection in vitro. 101 Finally, electron microscopy examinations, which proved SARS-CoV-2 hepatocellular infection, reported a pathological ER dilatation in infected hepatocytes, 40 which most probably will cause ER stress. Collectively, these data could indicate that SARS-CoV-2, as other coronaviruses, induces ER stress upon infection, and that the ER stress-induced de novo lipogenesis could also contribute to the development of steatosis in COVID-19 patients ( Figure 2 ).

De novo lipogenesis is also induced by the mammalian target of rapamycin (mTOR), 102 which is also the cardinal regulator of autophagy. 103 SARS-CoV has been previously shown to hijack the autophagy pathway through processes that rely on the viral non-structural protein 6 (nsp6), highly conserved in SARS-CoV-2. 104-106 Furthermore, mTOR hyper-activation has been observed in MERS-CoV-infected HuH7 cells, and inhibition of mTOR signalling pathway by rapamycin inhibits viral replication. 107 Given the recent observations that SARS-CoV-2 infection restricts autophagy, 108 it is tempting to speculate that SARS-CoV-2, SARS-CoV and MERS-CoV share a similar mTOR-dependent mechanism of infection. Furthermore, significantly increased mTOR activity has been revealed upon IL-6 stimulation. 109 

Cholestatic features such as bile duct proliferation, portal inflammatory infiltrates, and in some cases, canalicular/ductular bile plugs have been reported in post-mortem evaluations on COVID-19 patients. 49 In addition to hepatocellular features, bile duct changes, such as ductular proliferation have been observed in postmortem studies. 49 Notably, IL-6 is a strong cholangiocellular mitogen factor 128 and induces a proliferative and pro-inflammatory phenotype. 74, 129 Bile ducts from patients with COVID-19 could therefore be ex- Therefore, hepatic long-term follow-up for COVID-19 survivors who experienced a severe disease course, such as ARDS with ECMO and prolonged ICU admission might be considered. Early diagnosis is paramount to best manage symptoms and disease progression of SSC-CIP, which could be counteracted with anti-cholestatic, cholangio-protective drugs such as UDCA or more recently norUDCA. 132-134

Causes for hypoxic hepatitis are multifactorial. In general, cardiac failure, sepsis and respiratory failure account for more than 90% of all cases. [135] [136] [137] [138] Additionally, right-sided heart failure was found to aggravate liver injury by liver congestion as a result of elevated central venous pressure. 122, [135] [136] [137] [138] [139] [140] In cases of long-lasting hemodynamic and/or respiratory failure, hypoxia results in hepatic cell death, histopathologically defined as centrilobular necrosis. 141 COVID-19-associated ARDS remains the most common complication requiring critical care management including invasive ventilation, high levels of positive end-expiratory pressure (PEEP) and

vasoconstrictor therapy in case of hemodynamic instability. [142] [143] [144] [145] These factors may be accompanied by right ventricular dysfunction caused by high pulmonary vascular resistance as a result of hypoxaemia and hypercapnia during ARDS. 146, 147 Furthermore, COVID-19 causes a hyper-coagulate state with a significant incidence of pulmonary thrombotic complications aggravating acute right-sided heart failure and consequently liver congestion. 148 However, in the majority of cases, SARS-CoV-2 associated liver injury was generally mild and did not exceed >5 times the upper reference limit, therefore not fulfilling the diagnostic criteria for hypoxic hepaitis. 35 These findings were also obtained in critically ill patients referred to the ICU, suggesting that even in cases of severe respiratory failure during SARS-CoV-2 infection, the adequate oxygen supply to the liver is ensured by compensatory mechanisms. 35, 36, 39, [149] [150] [151] [152] [153] [154] 155 is also clearly associated with steatosis or glycogenosis. 156 Recently, the first case of DILI associated with tocilizumab use in a COVID-19 patient has been reported. 62 Tocilizumab undergoes minimal hepatic metabolism, and the most probable etiology for its hepatotoxic effect is the interference with the IL-6 pathway, which plays a key role in hepatic regeneration. 157 [166] [167] [168] Recently, viral nucleocapsid protein could be demonstrated within enterocytes by immunohistochemistry. 24 The Human Protein Atlas database further corroborates these observations, with intestinal cells exhibiting the highest pattern of ACE2 expression across the whole human cell type repertoire (data available at https://www.prote inatl as.org/ENSG0 00001 30234 -ACE2/ tissue). Moreover, human intestinal organoids have been shown to be permissive to SARS-CoV and SARS-CoV-2 infection. 169 Direct gastrointestinal infection has been reported also by biopsy-proven RNA and nucleocapsid protein detection in gastric, duodenal and rectal epithelia. 160 Interestingly, gastrointestinal symptoms may appear before or even in the absence of manifestations in the respiratory tract. 165 This suggests that the GI tract might be a primary site of COVID-19 infection, and therefore that oral-fecal transmission could be an alternative route of infection for SARS-CoV-2 (this has been extensively reviewed). 162, 170 We would like to propose the following putative way of SARS- 

Over the last months, several studies have highlighted the potential role of liver involvement in COVID-19 infection and pathology.

In this review, we analysed the published experimental and clinical findings concerning SARS-CoV-2 and previous coronavirus pandemics and proposed mechanisms concerning a putative SARS-CoV-2 hepatic tropism and the interplay between cytopathic and systemic effects in hepatic COVID-19 pathophysiology.

Elevated liver enzymes reflecting hepatic injury are common in COVID-19 patients both with and without chronic liver diseases. 35, 38, 43, 44 Interestingly, while early clinical studies identified significant raises exclusively in serum ALT and AST upon SARS-CoV-2 infection, which reflect hepatocellular damage, recent investigations and metanalyses also highlighted significant increases in ALP and γ-GT and therefore cholangiocellular injury. 35, 45 However, it is still not clear whether elevated serum liver biochemistries are causative for the worse outcome, or a consequence of the severe disease course.

In COVID-19 patients without pre-existing hepatic conditions who experienced liver damage, the injury is mostly mild. However, given the central role of the liver in endo-and xenobiotic/drug metabolism, coagulation, albumin and acute phase reactant production, hepatic dysfunction may impact on systemic disease pathophysiology of COVID-19. Long-term follow-up studies are required to explore potential long-term sequels of SARS-CoV-2 infection such as fibrosis.

Crucial questions remain open and need to be answered by future research: Which specific hepatic cells are infected by SARS-CoV-2?

Which molecular processes are dysregulated by the infection? What is the real contribution of direct cytopathic effects, cytokine storm, DILI or hypoxia in hepatic dysfunction? By which means could liver injury promote respiratory failure and predispose to a severe course of COVID-19?

The establishment of international registries collecting clinical reports of patients with liver diseases also tested positive for COVID-19, such as the COVID-Hep 175 and the SECURE-Cirrhosis, 176 together with molecular and translational research will surely help us shed some light on these intriguing questions and to set up more effective hepatoprotective programs for future pandemics. 

Insight into 2019 novel coronavirus -An updated interim review and lessons from SARS-CoV and MERS-CoV

Liver injury in COVID-19: management and challenges

Liver injury during highly pathogenic human coronavirus infections

COVID-19 and liver disease

Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

SARS-CoV-2 and viral sepsis: observations and hypotheses

The genome sequence of the SARS-associated coronavirus

The proximal origin of SARS-CoV-2

SARS and MERS: Recent insights into emerging coronaviruses

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Article SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response

Coronaviruses post-SARS: Update on replication and pathogenesis

SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway

An overview of their replication and pathogenesis

The 3a accessory protein of SARS coronavirus specifically interacts with the 5′UTR of its genomic RNA, using a unique 75 amino acid interaction domain

Understanding the accessory viral proteins unique to the severe acute respiratory syndrome (SARS) coronavirus

Ultrastructure and Origin of Membrane Vesicles Associated with the Severe Acute Respiratory Syndrome Coronavirus Replication Complex

SARS-Coronavirus Replication Is Supported by a Reticulovesicular Network of Modified Endoplasmic Reticulum

The intracellular sites of early replication and budding of SARS-coronavirus

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical Characteristics of Coronavirus Disease 2019 in China

Post-mortem viral dynamics and tropism in COVID-19 patients in correlation with organ damage. Virchows Arch

Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

ACE2: From vasopeptidase to SARS virus receptor

Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease

Comment Liver injury in COVID-19: management and challenges

COVID-19 and the liver: little cause for concern

COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?

Review article: COVID-19 and liver disease -what we know on 1st

Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19

Abnormal liver function tests in COVID-19 patients: relevance and potential pathogenesis

Liver diseases in COVID-19: Etiology, treatment and prognosis

Involvement of liver in COVID-19: systematic review and meta-analysis

COVID-19 and Liver

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

Reply to: Correspondence relating to "SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

Early dynamics of transmission and control of COVID-19: a mathematical modelling study

Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis

Bilirubin levels in patients with mild and severe Covid-19: A pooled analysis

Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease

COVID-19: Abnormal liver function tests

SARS-CoV-2 Infection Induces a Dual Response in Liver Function Tests: Association with Mortality during Hospitalization

Endothelial cell infection and endotheliitis in COVID-19

Pulmonary arterial thrombosis in covid-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series

Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study

Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations

Multiorgan and Renal Tropism of SARS-CoV-2

Biology of Viruses and Viral Diseases

Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection

SARS-CoV-2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID-19

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2

Expression of angiotensin-converting enzyme 2 in CCL4-induced rat liver fibrosis

Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease

Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators

First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Expression of trypsin by epithelial cells of various tissues, leukocytes, and neurons in human and mouse

Thinking outside the cell: Proteases regulate hepatocyte division

A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study

Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States

Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19

A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids

Cholangiocyte pathobiology

Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids

SARS-CoV-2 was found in the bile juice from a patient with severe COVID-19

High Mortality Rates for SARS-CoV-2 Infection in Patients with Pre-existing Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry

Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology

Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension

Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-ductligated rat

Gene Expression Profiles During Hepatic Stellate Cell Activation in Culture and In Vivo

Transcriptional regulation of Hepatic Stellate Cell activation in NASH

Fibrogenic Gene Expression in Hepatic Stellate Cells Induced by HCV and HIV Replication in a Three Cell Co

Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients

Immunohistochemical, in situ hybridization, and ultrastructural localization of SARSassociated coronavirus in lung of a fatal case of severe acute respiratory syndrome in Taiwan

In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19

Single Cell Analysis of ACE2 Expression Reveals the Potential Targets for 2019-nCoV

Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses

Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells

Liver-Resident Macrophage Necroptosis Orchestrates Type 1 Microbicidal Inflammation and Type-2-Mediated Tissue Repair during Bacterial Infection

Combination of mass cytometry and imaging analysis reveals origin, location, and functional repopulation of liver myeloid cells in mice

Liver Macrophages: Old Dogmas and New Insights

The Lung Macrophage in SARS-CoV-2 Infection: A Friend or a Foe?

Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease

SARS-CoV-2 induces a unique mitochondrial transcriptome signature

Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis

UPR Pathways Combine to Prevent Hepatic Steatosis Caused by ER Stress-Mediated Suppression of Transcriptional Master Regulators

Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein

The Coronavirus Spike Protein Induces Endoplasmic Reticulum Stress and Upregulation of Intracellular Chemokine mRNA Concentrations

The SARS Coronavirus 3a Protein Causes Endoplasmic Reticulum Stress and Induces Ligand-Independent Downregulation of the Type 1 Interferon Receptor

Severe Acute Respiratory Syndrome Coronavirus Triggers Apoptosis via Protein Kinase R but Is Resistant to Its Antiviral Activity

MTOR complex 1 regulates lipin 1 localization to control the srebp pathway

mTOR at the nexus of nutrition, growth, ageing and disease

Coronavirus Replication Complex Formation Utilizes Components of Cellular Autophagy

Coronavirus nsp6 proteins generate autophagosomes from the endoplasmic reticulum via an omegasome intermediate

Coronavirus NSP6 restricts autophagosome expansion

Antiviral potential of ERK/ MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis

Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and niclosamide as putative antiviral therapeutics

Mesenchymal stem cells-derived IL-6 activates AMPK/mTOR signaling to inhibit the proliferation of reactive astrocytes induced by hypoxic-ischemic brain damage

Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin

mTOR-Dependent Regulation of Ribosomal Gene Transcription Requires S6K1 and Is Mediated by Phosphorylation of the Carboxy-Terminal Activation Domain of the Nucleolar Transcription Factor UBF †

Nutrient-dependent mTORCl association with the ULK1-Atg13-FIP200 complex required for autophagy

MTORC1 phosphorylates UVRAG to negatively regulate autophagosome and endosome maturation

AMPK phosphorylation of raptor mediates a metabolic checkpoint

TSC2 mediates cellular energy response to control cell growth and survival

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science (80-. )

Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science (80-. )

Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data

Hepatic response to sepsis: Interaction between coagulation and inflammatory processes

Mechanisms of disease: Mechanisms and clinical implications of cholestasis in sepsis

Liver Injury and Failure in Critical Illness

Inflammation-induced cholestasis

Sepsis-associated cholestasis

The liver in sepsis: Patterns of response and injury

Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis

Modeling the Dynamics of Acute Phase Protein Expression in Human Hepatoma Cells Stimulated by IL-6

Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor β1, and activin A: Comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells

The dynamic biliary epithelia: Molecules, pathways, and disease

Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients

Hepatic Failure After Injury -A Common Pathogenesis With Sclerosing Cholangitis?

Ursodeoxycholic Acid Stimulates Cholangiocyte Fluid Secretion in Mice via CFTR-Dependent ATP Secretion

New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis

Hypoxic liver injury and cholestasis in critically ill patients

Hypoxic Hepatitis: A Review and Clinical Update

Hypoxic hepatitis in patients with cardiac failure: incidence in a coronary care unit and measurement of hepatic blood flow

Hypoxic hepatopathy: Pathophysiology and prognosis

Ischemic hepatitis: Clinical presentation and pathogenesis

Necroses of the Liver

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Intensive care during the coronavirus epidemic

Critical care management of adults with community-acquired severe respiratory viral infection

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)

Diagnostic workup, etiologies and management of acute right ventricle failure: A stateof-the-art paper

The Right Ventricle in COVID-19 Patients

Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected with Pulmonary CT Angiography

Liver Biochemistries in Hospitalized Patients With COVID-19

liver enzyme elevation in coronavirus disease 2019: a multicenter, retrospective, Cross-Sectional Study

Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1827 Patients in a Major U.S. Hospital Network

Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19

High rates of 30-day mortality in patients with cirrhosis and COVID-19

Liver Injury in Critically Ill and Noncritically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (National Institute of Diabetes and Digestive and Kidney Diseases

Clinical and Research Information on Drug-Induced Liver Injury (National Institute of Diabetes and Digestive and Kidney Diseases

Covid-19 and the digestive system

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Evidence for Gastrointestinal Infection of SARS-CoV-2

Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia

Potential Fecal Transmission of SARS-CoV-2: Current Evidence and Implications for Public Health

Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China

The small intestine, an underestimated site of SARS-CoV-2 infection: from Red Queen effect to probiotics

Specific ACE2 Expression in Small Intestinal Enterocytes may Cause Gastrointestinal Symptoms and Injury after 2019-nCoV Infection

Digestive system is a potential route of COVID-19: An analysis of single-cell coexpression pattern of key proteins in viral entry process

SARS-CoV-2 productively infects human gut enterocytes. Science (80-. )

COVID-19: faecal-oral transmission?

Bile acids and ceramide overcome the entry restriction for GII.3 human norovirus replication in human intestinal enteroids

The intestinal regionalization of acute norovirus infection is regulated by the microbiota via bile acid-mediated priming of type III interferon

ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection

COVID-19 and the endocrine system: exploring the unexplored